Know what’s really happening at
Tavo Biotherapeutics before you sign on.
- On the roadmap
- Ophthalmology
- Biotechnology
- Drug Discovery
Tavo Biotherapeutics is developing injectionless therapies for front- and back-of-the-eye diseases, targeting a significant unmet need in ophthalmology. Founded in 2024 and backed by top-tier biotech investors, the company is pursuing a novel approach to preserving vision without the burden of ocular injections.
How we do it.
Most "AI market intel" is a summarized crawl of press releases. This Altis research is built from our knowledge graph of sector expert calls, synthesized with public sources.
Tavo Biotherapeutics
- Total USD Funding
- $17M
- Year Founded
- 2024
- Lead Investor
- Pureos Bioventures
- Company Size
- 11-50
- Headquarters
- Dorchester, Wisconsin, United States
- Founder
- Monica M. Jablonski
- Growth Signal
- Headcount Surge
Press reported
Altis Verified
What's in the report
Most "AI market intel" is a summarized crawl of press releases. This is what customers, competitors, and former employees actually told us.
Market Overview
Market structure, where the company sits, and growth drivers.
- market map
- Ophthalmology landscape
- Ophthalmology growth rate
- CAGR
Total Addressable Market
Bottom-up TAM / SAM / SOM.
- Tavo Biotherapeutics TAM
- Ophthalmology market size
- market opportunity
Company Overview
What the company does and how it operates.
- what does Tavo Biotherapeutics do
- Tavo Biotherapeutics product
- business model
Product / Go-to-Market
Product, GTM motion, ICP, and who buys.
- Tavo Biotherapeutics customers
- who uses Tavo Biotherapeutics
- Tavo Biotherapeutics ICP
- go-to-market
Competitive Dynamics
The Altis Market Map and the Altis Win-Rate Index.
- Tavo Biotherapeutics competitors
- Tavo Biotherapeutics alternatives
- who competes with Tavo Biotherapeutics
- Tavo Biotherapeutics win rate
Customer Signals
Retention, satisfaction, and win/loss signals.
- Tavo Biotherapeutics reviews
- Tavo Biotherapeutics NRR
- Tavo Biotherapeutics churn
- current customers
- switching costs
Investment Debates
Investment thesis, moat, bull/bear, and key risks.
- Tavo Biotherapeutics investment thesis
- Tavo Biotherapeutics moat
- bull case bear case
- Tavo Biotherapeutics risk factors
Monetization & Financials
Business model, revenue model, and unit economics.
- Tavo Biotherapeutics ARR
- Tavo Biotherapeutics revenue
- Tavo Biotherapeutics valuation
- unit economics
Team and culture
Founders, leadership, and org.
- Tavo Biotherapeutics founders
- Tavo Biotherapeutics CEO background
- leadership team
- headcount
Trusted by
Ready to see the full picture?
Analysis based on Altis company scan data including funding records, growth signals, and company profile information.